Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated...( Targets Fastest-Growing Segme...)

Targets Fastest-Growing Segment of Chemistry Testing Market

FULLERTON, Calif., March 6 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it has launched the UniCel DxC 880i Synchron(R) Access(R) clinical system, an integrated work cell which consolidates chemistry and immunoassay testing targeted to high-volume laboratories. The latest addition to the company's work cell family combines Beckman Coulter's market-leading chemistry system, the UniCel DxC 800, and the industry's highest-throughput immunoassay system, the UniCel DxI 800.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

The DxC 880i advances the company's strategy of delivering standardized work cell solutions for greater laboratory efficiency. Three additional work cells, designed for different testing volumes, are in development. Work cells are the fastest-growing segment of the chemistry testing market, growing at more than 15 percent each year.

"Work cells are often the first step in automating a clinical diagnostic laboratory, bringing substantial workflow benefits," said Scott Garrett, president and CEO. "Capable systems like these are essential for laboratories looking to streamline and simplify their operations. Our new work cells have the potential to improve hospital productivity by driving up lab productivity, improving patient health and reducing the cost of care."

"Importantly, UniCel DxC 800 chemistry systems or DxI(R) 800 immunoassay systems already installed in laboratories may be upgraded in the field to the new DxC 880i configuration. This flexible approach allows laboratories to choose a Beckman Coul
'/>"/>